Michelson Diagnostics has debuted a prototype version of its clinical Optical Coherence Tomography (OCT) probe and processing system, dubbed Vivosight.
Two variants of the new Vivosight probe were issued in Michelson Diagnostics' preliminary specification. One is a version with X-Y scanning, to enable 3D mapping of flat tissue such as skin. The other is a version equipped with a rigid endoscope, suitable for internal applications. The unique multi-beam design provides double the image resolution (i.e. better than 10 µm) available from conventional single-beam designs, resulting in crisper, clearer OCT images, showing more clinical detail.
"We will be applying for a CE-mark for the product, which will enable sales for clinical use in Europe, in the spring 2009 time-frame." said Jon Holmes, Chief Executive, "This will be followed by a 510(k) for the equivalent in the US market."
Michelson Diagnostics is leading the way in applying Multi-Beam OCT to the diagnosis, monitoring and treatment of cancer, particularly dermal and oral cancer. They are working closely with leading clinicians, who believe that Multi-Beam OCT, by providing a new, detailed window into the body, will accelerate the care of cancer, enabling faster, more accurate treatment that will save lives and produce substantial cost savings to the medical services.
Vivosight is planned for launch in late spring 2009.